Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

N Katoh

Showing results (261-270 of 265) with videos related to

Pageof 27
Sort By:
You have reached the last page of results.This site can display upto 265 results.
The British Journal of Dermatology|November 12, 2020
Recommended core outcome instruments for health-related quality of life, long-term control and itch intensity in atopic eczema trials: results of the HOME VII consensus meetingK S Thomas, C A Apfelbacher, J R Chalmers, et al.
The British Journal of Dermatology|October 1, 2020
Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2)A Wollenberg, A Blauvelt, E Guttman-Yassky, et al.
The British Journal of Dermatology|January 4, 2021
Recommended core outcome instruments for health-related quality of life, long-term control and itch intensity in atopic eczema trials: results of the HOME VII consensus meetingK S Thomas, C A Apfelbacher, J R Chalmers, et al.
The British Journal of Dermatology|July 2, 2014
Report from the third international consensus meeting to harmonise core outcome measures for atopic eczema/dermatitis clinical trials (HOME)J R Chalmers, J Schmitt, C Apfelbacher, et al.
Allergy|March 30, 2016
Global Allergy Forum and 3rd Davos Declaration 2015: Atopic dermatitis/Eczema: challenges and opportunities toward precision medicineT Bieber, C Akdis, R Lauener, et al.
Pageof 27

Showing results (261-270 of 265) with videos related to

Sort By:
Pageof 27
You have reached the last page of results.This site can display upto 265 results.
The British Journal of Dermatology|November 12, 2020
Recommended core outcome instruments for health-related quality of life, long-term control and itch intensity in atopic eczema trials: results of the HOME VII consensus meetingK S Thomas, C A Apfelbacher, J R Chalmers, et al.
The British Journal of Dermatology|October 1, 2020
Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2)A Wollenberg, A Blauvelt, E Guttman-Yassky, et al.
The British Journal of Dermatology|January 4, 2021
Recommended core outcome instruments for health-related quality of life, long-term control and itch intensity in atopic eczema trials: results of the HOME VII consensus meetingK S Thomas, C A Apfelbacher, J R Chalmers, et al.
The British Journal of Dermatology|July 2, 2014
Report from the third international consensus meeting to harmonise core outcome measures for atopic eczema/dermatitis clinical trials (HOME)J R Chalmers, J Schmitt, C Apfelbacher, et al.
Allergy|March 30, 2016
Global Allergy Forum and 3rd Davos Declaration 2015: Atopic dermatitis/Eczema: challenges and opportunities toward precision medicineT Bieber, C Akdis, R Lauener, et al.
Pageof 27